EA2222 (Colorectal Cancer with Liver Metasases)

Purpose of this Study

We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.

Who Can Participate?

Eligibility

Adults ages 18+ who:<ul>
<li>Are diagnosed with unresectable colorectal cancer</li>
<li>Have metastases to the liver</li>
<li>Have received a 3-6 month course of previous first-line chemotherapy</li>
<li>Have not received radiation therapy directed toward the liver</li></ul>

For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.

What is Involved?

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:<ul>
<li>Group 1 will get will get chemotherapy that's given in the traditional manner and directly into the hepatic artery</li>
<li>Group 2 will get will get chemotherapy that's given in the traditional manner only</li></ul>

Study Details

Full Title

EA2222: A Randomized Phase III Study of Systemic Therapy With or Without Hepatic arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial

Principal Investigator

Hope
Uronis

Protocol Number

PRO00114675

NCT ID

NCT05863195

Phase

III

Enrollment Status

Open to Enrollment